Breaking News, Promotions & Moves

FUJIFILM Diosynth Biotechnologies Appoints Richard McAvoy CFO

McAvoy will be responsible for financial strategies, financial activities, and financial management contributing to the company’s growth strategy.

By: Kristin Brooks

Managing Editor, Contract Pharma

FUJIFILM Diosynth Biotechnologies, a contract development and manufacturing organization (CDMO) for biologics, vaccines, advanced therapies and oncolytic viruses, has appointed Richard McAvoy, currently the Holly Springs, NC site head and vice president of business support, as chief financial officer effective April 1, 2024. McAvoy will be responsible for the company’s financial strategies, overseeing financial activities, and financial management contributing to the company’s growth strategy. McAvoy will be based in Holly Springs.
 
McAvoy brings extensive experience to his new global position as CFO, most recently serving as site head for the company’s $2 billion large-scale cell culture manufacturing facility in Holly Springs, poised to be the largest CDMO in North America once completed. Previously he held key roles within the company as global CAPEX counsel and head of business support. Prior to joining the company, he held leadership roles at Novo Nordisk and Alston & Bird LLP.
 
“I’m thrilled to congratulate Richard on his new role. We look forward to Richard’s contributions as we execute on our growth strategy,” said Lars Petersen, president and chief executive officer of FUJIFILM Diosynth Biotechnologies. “His proven leadership driving a People First and Partners for Life mindset with our major clients and solid track record of leading in a landscape of highly complex stakeholders, will contribute to the continued success and growth of our company.”
 
“I am honored to be appointed to the role of CFO at FUJFILM Diosynth Biotechnologies and contribute to the success of this dynamic organization,” said McAvoy. “This company has a rich history and an extremely bright future. I look forward to working collaboratively with our talented team and driving financial strategies that support our near-and-long-term objectives.”
 
Jordan Ulrich, vice president of project delivery, has been appointed interim site head of Holly Springs, effective April 1. Ulrich has been instrumental in initiating and driving the Holly Springs expansion and will ensure a stable delivery of the site towards its completion.
 
McAvoy will succeed Michael Lyons, who has been appointed senior vice president, deputy head of the Small-Scale Business Unit effective April 1.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters